Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

Abstract Background Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. While most MDR/RR-TB patients do not receive treatment, many who do are treated for 18 months or more. A short...

Descrición completa

Detalles Bibliográficos

Principais autores:	L. Guglielmetti, E. Ardizzoni, M. Atger, E. Baudin, E. Berikova, M. Bonnet, E. Chang, S. Cloez, J. M. Coit, V. Cox, B. C. de Jong, C. Delifer, J. M. Do, D. Dos Santos Tozzi, V. Ducher, G. Ferlazzo, M. Gouillou, A. Khan, U. Khan, N. Lachenal, A. N. LaHood, L. Lecca, M. Mazmanian, H. McIlleron, M. Moschioni, K. O’Brien, O. Okunbor, L. Oyewusi, S. Panda, S. B. Patil, P. P. J. Phillips, L. Pichon, P. Rupasinghe, M. L. Rich, N. Saluhuddin, K. J. Seung, M. Tamirat, L. Trippa, M. Cellamare, G. E. Velásquez, S. Wasserman, P. J. Zimetbaum, F. Varaine, C. D. Mitnick
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2021-09-01
Series:	Trials
Assuntos:	Rifampin-resistant tuberculosis Rifampicin-resistant tuberculosis Bedaquiline Delamanid Linezolid Clofazimine
Acceso en liña:	https://doi.org/10.1186/s13063-021-05491-3
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!